The impact of exogenous luteinizing hormone on IVF/ICSI cycles parameters

Česká verzia

Authors: S. Toporcerová; P. Urdzík; M. Popelková; K. Balasičová; A. Ostró
Authors place of work: II. gynekologicko-pôrodnícka klinika Lekárskej fakulty Univerzity P. J. Šafárika a Univerzitnej nemocnice L. Pasteura, Košice, prednosta prof. MUDr. A. Ostró, CSc.
Published in the journal: Ceska Gynekol 2011; 76(4): 268-273

Summary

Objective:
To evaluate the effect of exogenous luteinizing hormone on IVF/ICSI success.

Design:
Retrospective clinical study.

Setting:
2^nd Department of Gynaecology and Obstetrics, Medical Faculty and L. Pasteur University Hospital Košice, Slovak Republic.

Methods:
Individual parameters and clinical pregnancy rate of 232 IVF/ICSI cycles were compared in dependence on stimulation protocol (pure rFSH vs. rFSH and 75 IU rLH from S7).

Results:
There was no statistically significant difference in IVF/ICSI success between individual groups and subgroups, but we demonstrated the increase in clinical pregnancy rate per ET in agonist cycles group with exogenous LH activity totally above 11% (27.6% vs. 38.6%), in patients under 35 years above 12% (30.4% vs. 42.6%) and in patients over 35 years above 14% (16.7% vs. 30.8%). In antagonist cycles group there was demonstrated the increase in clinical pregnancy rate only in women over 35 years - above 14% (13.3% vs. 30.8%).

Conclusions:
Despite of negative statistical analyses, from the clinical point of view we can strongly recommend the LH addition during COH, especially in agonist cycles and in older women.

Key words:
IVF, ICSI, LH, luteinizing hormone, ovarian hyperstimulation.

Zdroje

1. Al-Inany, HG., Abou-Setta, AM., Aboulghar, MA., et al. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online, 2008, 1, p. 81-88.

2. Alviggi, C., Mollo, A., Clarizia, R., et al. Exploiting LH in ovarian stimulation. Reprod Biomed Online, 2006, 2, p. 221-233.

3. Bosch, E., Labarta, E., Crespo, J., et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril, 2010, s. doi:10.1016/j.fertnstert.2010.1010.1021.

4. Cedrin-Durnerin, I., Grange-Dujardin, D., Laffy, A., et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod, 2004, 9, p. 1979-1984.

5. Cohen, J., Wells, D., Munne, S. Removal of 2 cells from cleavage stage embryos is likely to reduce the efficacy of chromosomal tests that are used to enhance implantation rates. Fertil Steril, 2007, 3, p. 496-503.

6. Coomarasamy, A., Afnan, M., Cheema, D., et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod, 2008, 2, p. 310-315.

7. Durnerin, CI., Erb, K., Fleming, R., et al. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod, 2008, 2, p. 421-426.

8. Check, JH., Davies, E., Brasile, D., et al. A prospective comparison of in vitro fertilization (IVF) outcome following controlled ovarian hyperstimulation (COH) regimens using follitropin alpha exclusively or with the addition of low dose human chorionic gonadotropin (hCG) and ganirelix. Clin Exp Obstet Gynecol, 2009, 4, p. 217-218.

9. Kim, YJ., Ku, SY., Jee, BC., et al. Effects of adding luteinizing hormone activity to gonadotropin releasing hormone antagonist protocols may differ according to age. Gynecol Endocrinol, 2010, 4, p. 256-260.

10. Kim, YJ., Ku, SY., Jee, BC., et al. Tri-pronucleated zygotes may occur less frequently in luteinizing hormone activity-added cycles. Gynecol Endocrinol, 2010, s. [Epub ahead of print].

11. Mastenbroek, S., Twisk, M., Van Echten-Arends, J., et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med, 2007, 1, p. 9-17.

12. Matorras, R., Prieto, B., Exposito, A., et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online, 2009, 6, p. 879-887.

13. Pacchiarotti, A., Sbracia, M., Frega, A., et al. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril, 2010, 6, p. 2467-2469.

14. Requena, A., Landeras, JL., Martinez-Navarro, L., et al. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles? Hum Fertil (Camb), 2010, 1, p. 41-49.

15. Toporcerová, S., Hredzák, R., Ždilová, V., a kol. Exogénna suplementácia luteinizačného hormónu v cykloch IVF. Prakt Gynek, 2004, 5, s. 21.

16. Toporcerová, S., Hredzák, R., Ostró, A., a kol. Vplyv sérových hladín uteinizačného hormónu počas kontrolovanej ovariálnej hyperstimulácie na výsledky cyklu IVF. Čes Gynek, 2005, 4, s. 247-253.

17. Toporcerová, S., Hredzák, R., Ostró, A., a kol. Vplyv exogénnej suplementácie LH počas kontrolovanej ovariálnej hyperstimulácie na výsledky cyklu IVF. Čes Gynek, 2005, 3, s. 187-191.

18. Toporcerová, S., Hredzák, R., Ždilová, V., a kol. Úloha LH aktivity v IVF cykloch s použitím antagonistov GnRH. Reprodukčná medicína – zborník abstraktov, 2005, s. 117-118.

19. Weghofer, A., Munne, S., Brannath, W., et al. The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles. Fertil Steril, 2009, 3, p. 937-942.

20. Welcker, JT., Nawroth, F., Bilger, W. Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study. Reprod Biol Endocrinol, 2010, p. 111.

21. Xu, SR., Li, Y., Liu, H., et al. Use of recombinant human luteinizing hormone for ovulation stimulation in in vitro fertilization-embryo transfer. Zhonghua Fu Chan Ke Za Zhi, 2010, 6, p. 420-423.